Navigation Links
Additive Anti-Tumor Activity of NKTR-102 in Combination With Bevacizumab Highlighted in Positive Preclinical Data Presented at AACR Meeting
Date:4/14/2008

rs are attached to therapeutic agents, and it is applicable to most major drug classes, including proteins, peptides, antibody fragments, small molecules, and other drugs.

Nektar PEGylation technology is also used in eight additional approved partnered products in the U.S. or Europe today, including Roche's PEGASYS(R) for hepatitis C and Amgen's Neulasta(R) for neutropenia.

About Nektar

Nektar Therapeutics is a biopharmaceutical company that develops and enables differentiated therapeutics with its industry-leading PEGylation and pulmonary drug development technology platforms. Nektar PEGylation and pulmonary technology, expertise, manufacturing capabilities have enabled eight approved products for partners, which include the world's leading pharmaceutical and biotechnology companies. Nektar also develops its own products by applying its PEGylation and pulmonary technology platforms to existing medicines with the objective to enhance performance, such as improving efficacy, safety and compliance.

This press release contains forward-looking statements regarding the potential of NKTR-102 and the company's PEGylation technology platform. These forward-looking statements involve important risks and uncertainties, including but not limited to: (i) preclinical testing and clinical trials for NKTR-102 are long, expensive and uncertain processes, (ii) because the NKTR- 102 product development programs are in the early phases of clinical development, the risk of failure is high and can occur at any stage of development, (iii) the company may fail to obtain regulatory approval of NKTR- 102, (iv) the timing or success of the commencement or conclusion of NKTR-102 clinical trials is subject to a number of uncertainties including but not limited to clinical design, patient enrollment, regulatory requirements and clinical outcomes (v) potential competition from existing approved products (branded or generic) or product candidates under development by o
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Interim Phase 2 Data for Exelixis XL880 Show Anti-Tumor Activity in Papillary Renal Cell Cancer
2. BiPar Announces Preclinical Data Demonstrating Anti-Tumor Activity With BSI-401, Its Second-Generation PARP Inhibitor
3. Human Genome Sciences Presents New Data Showing Anti-Tumor Activity And Safety Of Trail Receptor Antibodies In Combination With Chemotherapy
4. Updated Phase 1 Data for Exelixis XL184 Demonstrate Pharmacodynamic and Clinical Anti-Tumor Activity
5. Nuvelo Announces Preclinical Data for NU206 Demonstrating Potent Therapeutic Activity in Oral Mucositis Models
6. Update From Mipomersen Extended Dosing Study Continues to Show That Mipomersen Is Well Tolerated and Maintains Activity in Patients Treated for Up to 16 Months
7. Intra-Cellular Therapies Announces the Discovery of Potent Antidepressant Activity in ITI-007
8. Intra-Cellular Therapies Announces the Discovery of Potent Antidepressant Activity in ITI-007/ITI-722
9. Rigels R788 Shows Preclinical Activity in Type 1 Diabetes Model
10. ImQuest Publishes Results of Important Structure Activity Relationship Program on Dual Acting Pyrimidinediones
11. Evotecs EVT 101 Shown to Penetrate the Brain in Man and to Modulate Brain Activity During the Performance of Cognitive Tasks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)... DIEGO , Sept. 29, 2014  Volcano ... company focused on improving patient and economic outcomes ... innovative minimally invasive coronary and peripheral visualization, physiology ... letter to its Board of Directors from Engaged ... in response:  Volcano welcomes the ...
(Date:9/29/2014)... TOKIO und SAN ... -- Daiichi Sankyo Company, Ltd. (nachstehend Daiichi ... AMBI ) gaben heute gemeinsam ... Sankyo das ausgegebene Aktienkapital von Ambit Biosciences ... über ein Ausschreibungsangebot und anschließenden Zusammenschluss mit ...
(Date:9/29/2014)... 29, 2014 The global implantable ... by 2018, recording a CAGR of 8.8% from 2012 ... Market - Global Industry Analysis, Size, Share, Trends and ... U.S.-based market intelligence company. The market, which ... an increasing occurrence of cardiovascular diseases, diabetic retinopathy, colorectal ...
Breaking Medicine Technology:Volcano Issues Statement Regarding Letter From Engaged Capital 2Volcano Issues Statement Regarding Letter From Engaged Capital 3Daiichi Sankyo wird Ambit Biosciences übernehmen 2Daiichi Sankyo wird Ambit Biosciences übernehmen 3Daiichi Sankyo wird Ambit Biosciences übernehmen 4Daiichi Sankyo wird Ambit Biosciences übernehmen 5Daiichi Sankyo wird Ambit Biosciences übernehmen 6Daiichi Sankyo wird Ambit Biosciences übernehmen 7Daiichi Sankyo wird Ambit Biosciences übernehmen 8Global Implantable Drug Delivery Devices Market to Grow at 8.8% CAGR to US$ 21.1 billion by 2018: Transparency Market Research 2Global Implantable Drug Delivery Devices Market to Grow at 8.8% CAGR to US$ 21.1 billion by 2018: Transparency Market Research 3Global Implantable Drug Delivery Devices Market to Grow at 8.8% CAGR to US$ 21.1 billion by 2018: Transparency Market Research 4
... , NEW YORK, Nov. 10 Reportlinker.com ... is available in its catalogue. , ... http://www.reportlinker.com/p0161946/Metabolic-Endocrinology-Hypocalcemia.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=prnewswire , Life ... information on the current drug pipeline. This ...
... Life Spine announced today the launch of the AVATAR ... The AVATAR MIS System provides a unique approach to ... delivery system with a variety of rod insertion mechanisms, ... as well as pathologies requiring in-situ reduction, distraction, and ...
Cached Medicine Technology:Reportlinker Adds Metabolic Endocrinology Hypocalcemia 2Reportlinker Adds Metabolic Endocrinology Hypocalcemia 3
(Date:9/29/2014)... CuteBobble.com, an experienced supplier that provides ... new collection of custom bobbleheads for Christmas. ... these quality items. Moreover, all the company’s old and ... code: 10USDOFF). The promotion will last until December 15, ... new designs of custom bobbleheads . Now, our ...
(Date:9/29/2014)... (PRWEB) September 30, 2014 Shoulder pain is ... those with persistent shoulder pain generates nearly ¾ of the ... 20-33% of all adults will experience shoulder pain, and of ... has also been reported that 1 in 4 people with ... less than a year. , “This is a real problem, ...
(Date:9/29/2014)... FL (PRWEB) September 30, 2014 Only ... than $20 can improve well-being, says Sublime Beauty®.The secret ... in Skin Brushes and have introduced thousands to this ... , Heshelow was interviewed recently on the eHealth ... to learn more . , "We have just released ...
(Date:9/29/2014)... (PRWEB) September 30, 2014 Foundations Recovery ... to announce the start of its 40th national conference ... Greenwald as a featured keynote speaker at the Moments ... experts specializing in the fields of addiction and mental ... Palm Beach, Fla., September 29 – October 2, 2014, ...
(Date:9/29/2014)... Atlanta, GA (PRWEB) September 30, 2014 In ... Whiter Image Dental has recently implemented some principles from the ... company as a whole. Whiter Image CEO Brad Stevens ... the “Most eye-opening seminar [he had] ever been to.” The ... business leaders produce great results by tapping into the desire ...
Breaking Medicine News(10 mins):Health News:Customers Can Get $10 Discount Coupons For Christmas When Ordering Custom Bobbleheads At CuteBobble.com 2Health News:KORT Physical Therapist Shines a Light on Shoulder Pain and Latest Treatments 2Health News:7 Easy Steps to Skin Brushing Guide Available from Sublime Beauty®; Body Brushing Details Revealed in eHealth Radio Network Interview 2Health News:Glenn Greenwald Addresses Drug Decriminalization at Foundations Recovery Network’s 40th National Conference 2Health News:Glenn Greenwald Addresses Drug Decriminalization at Foundations Recovery Network’s 40th National Conference 3Health News:Whiter Image Launches Four Disciplines of Execution Initiative into Corporate Strategy 2
... 2009 The world,s top lung cancer specialists, medical ... Francisco, CA for the 13th World Conference on Lung ... Study of Lung Cancer (IASLC). Prevention and early detection ... remains one of the hardest cancers to detect in ...
... ... , ... August 2, 2009 -- United Benefit Advisors, LLC (UBA), one of the nation,s leading ... health management. , , , , ,"The majority of employers clearly recognize the potential ...
... cancer patients who have progressed on a cetuximab-containing regimen ... reported today at the annual meeting of the International ... cetuximab (Erbitux) and erlotinib (Tarceva) inhibit the epidermal growth ... once a patient progresses on one EGFR inhibitor they ...
... FRANCISCO, August 1, 2009 The world,s top lung ... week in San Francisco, CA for the 13th World ... Association for the Study of Lung Cancer (IASLC). According ... WCLC, targeted therapies, as first-line treatment, have the potential ...
... FASTRACK ... Billing & Home HealthCare Agency Billing Software System. The FASTRACK Integrated IV, HME ... single common Microsoft SQL database that allows for the connection of remote sites via ... ...
... ... by Richard K. Riegelman, is hard-wired to the Association of American Colleges ... The book is an important part of a growing movement of several ... as a critical component of good citizenship and a prerequisite for taking ...
Cached Medicine News:Health News:Diagnostic tools and innovative therapies improve patient prognosis 2Health News:Diagnostic tools and innovative therapies improve patient prognosis 3Health News:Diagnostic tools and innovative therapies improve patient prognosis 4Health News:Diagnostic tools and innovative therapies improve patient prognosis 5Health News:Diagnostic tools and innovative therapies improve patient prognosis 6Health News:Employers Recognize Potential Impact of Employee Health Management on Future Plan Costs 2Health News:Employers Recognize Potential Impact of Employee Health Management on Future Plan Costs 3Health News:Fox Chase finds that lung cancer patients respond to erlotinib following cetuximab therapy 2Health News:Advanced targeted therapies effective as first-line treatment for lung cancer 2Health News:Advanced targeted therapies effective as first-line treatment for lung cancer 3Health News:Advanced targeted therapies effective as first-line treatment for lung cancer 4Health News:Advanced targeted therapies effective as first-line treatment for lung cancer 5Health News:Advanced targeted therapies effective as first-line treatment for lung cancer 6Health News:Advanced targeted therapies effective as first-line treatment for lung cancer 7Health News:Advanced targeted therapies effective as first-line treatment for lung cancer 8Health News:Fastrack Release First Integrated HME Billing, Infusion Pharmacy & Home Care Agency Software in a Microsoft Environment 2Health News:New Book by Leading Authority Responds to National Initiative to Bring Undergraduate Public Health Education to All American Colleges and Universities 2Health News:New Book by Leading Authority Responds to National Initiative to Bring Undergraduate Public Health Education to All American Colleges and Universities 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: